Evidence-based Appraisal of the DAPA-HF Trial

Evidence-based Appraisal of the DAPA-HF Trial

Bibliographic Details
Main Authors:	Anthony Sengul, Edison Escobar, Cynthia Jackevicius
Format:	Article
Language:	English
Published:	California Pharmacists Association 2020-10-01
Series:	Journal of Contemporary Pharmacy Practice
Online Access:	https://meridian.allenpress.com/jcphp/article/67/3/24/446411/Evidence-based-Appraisal-of-the-DAPA-HF-Trial

Similar Items

Evidence-based Appraisal of the RECOVERY Trial
by: Shogo Kono, et al.
Published: (2021-08-01)

DAPA-HF study: Are the benefits uniform across non-diabetic subgroups
by: Anil Pareek, et al.
Published: (2020-09-01)

DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure
by: Edgardo Kaplinsky
Published: (2020-02-01)

The DAPA Trial in the Context of Previous Prophylactic ICD Landmark Trials
by: Danielle Haanschoten, et al.
Published: (2021-10-01)

Results of the DAPA-CKD trial and their impact on clinical practice
by: O.V. Bilchenko
Published: (2023-06-01)

Towards quadruple therapy for heart failure with reduced ejection fraction: DAPA-HF secondary analysis data
by: Zh. D. Kobalava, et al.
Published: (2020-06-01)

Estimated Population Prevalence of Heart Failure with Reduced Ejection Fraction in Spain, According to DAPA-HF Study Criteria
by: Anna Camps-Vilaró, et al.
Published: (2020-07-01)

Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA‐HF Trials
by: Ankeet S. Bhatt, et al.
Published: (2024-03-01)

Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion
by: Milton Packer
Published: (2019-10-01)

Fluid homeostatic action of dapagliflozin in patients with chronic kidney disease: the DAPA-BODY Trial
by: Kentaro Oka, et al.
Published: (2023-12-01)

POS-832 DAPAGLIFLOZIN IN IgA NEPHROPATHY: FINDINGS FROM THE DAPA-CKD TRIAL
by: H. Lambers Heerspink, et al.
Published: (2021-04-01)

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial
by: Glenn M. Chertow, et al.
Published: (2023-05-01)

Dementia And Physical Activity (DAPA) trial of moderate to high intensity exercise training for people with dementia: randomised controlled trial
by: Lamb, S, et al.
Published: (2018)

DAPA: Differential Analysis aided Power Attack on (Non-) Linear Feedback Shift Registers
by: Siang Meng Sim, et al.
Published: (2020-12-01)

DAPA: Differential Analysis aided Power Attack on (Non-) Linear Feedback Shift Registers
by: Siang Meng Sim, et al.
Published: (2020-12-01)

Aerobic and strength training exercise programme for cognitive impairment in people with mild to moderate dementia: the DAPA RCT
by: Lamb, S, et al.
Published: (2018)

The Reporting Frequency of Ketoacidosis Events with Dapagliflozin from the European Spontaneous Reporting System: The DAPA-KETO Study
by: Gabriella di Mauro, et al.
Published: (2022-02-01)

Aerobic and strength training exercise programme for cognitive impairment in people with mild to moderate dementia: the DAPA RCT
by: Sarah E Lamb, et al.
Published: (2018-05-01)

Dementia and Physical Activity (DAPA) - an exercise intervention to improve cognition in people with mild to moderate dementia: study protocol for a randomized controlled trial
by: Atherton, N, et al.
Published: (2016)

The Efficacy and Safety of the Combined Therapy of Sodium-Glucose Co-Transporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitor in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis of the EMPEROR-Reduced and DAPA-HF Sub-Analysis
by: Yanxia Lin, et al.
Published: (2022-05-01)

POS-336 THE IMPACT OF CHRONIC KIDNEY DISEASE AND CLINICAL EVENTS ON PATIENT HEALTH RELATED QUALITY OF LIFE IN DAPA-CKD
by: P. MCEWAN, et al.
Published: (2021-04-01)

POS-831 THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH eGFR <30 mL/min/1.73m2: FINDINGS FROM THE DAPA-CKD TRIAL
by: G.M. Chertow, et al.
Published: (2021-04-01)

Does structured exercise improve cognitive impairment in people with mild to moderate dementia? A cost-effectiveness analysis from a confirmatory randomised controlled trial: The Dementia and Physical Activity (DAPA) Trial
by: Khan, I, et al.
Published: (2018)

Short-term changes in klotho and FGF23 in heart failure with reduced ejection fraction—a substudy of the DAPA-VO2 study
by: Carmen Mora-Fernández, et al.
Published: (2023-08-01)

Role of the Dihydrodipicolinate Synthase DapA1 on Iron Homeostasis During Cyanide Assimilation by the Alkaliphilic Bacterium Pseudomonas pseudoalcaligenes CECT5344
by: Alfonso Olaya-Abril, et al.
Published: (2020-01-01)

Evidence-Based Medicine Appraisal Companions
by: Rani Gereige
Published: (2006-10-01)

Practicing evidence-based Orthodontics: How to critically appraise a randomized controlled trial
by: Joana Cunha-Cruz
Published: (2015-04-01)

Finding and appraising evidence.
by: McCulloch, P, et al.
Published: (2006)

Sub-analyses of the DAPA-CKD study: new data on the use of sodium-glucose cotransporter type 2 inhibitor in the treatment of chronic kidney disease
by: Minara S. Shamkhalova, et al.
Published: (2022-11-01)

Sodium-Glucose Cotransporter-2 Inhibitors—Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials
by: Tomohito Gohda, et al.
Published: (2022-11-01)

ADDition of DAPAgliflozin, Sodium-Glucose Cotransporter-2 Inhibitor to Angiotensin Receptor Blocker-Neprilysin Inhibitors Non-Responders in Patient with Refractory Heart Failure with Reduced Ejection Fraction (ADD DAPA trial)
by: Pankaj Jariwala, MD, DNB, DNB, MNAMS, FACC, FSCAI, et al.
Published: (2021-09-01)

Dynamics of the termolecular (HF+HF+HF) reaction
by: Ibrahim Ali , Noorbatcha
Published: (2006)

Dynamics of the termolecular (HF+HF+HF) reaction
by: Arifin, B., et al.
Published: (2006)

PART 3. APPRAISING THE EVIDENCE
by: LAI NM
Published: (2009-01-01)

The appraisal of medical scientific evidence
by: Álvaro Nagib Atallah

The DAPA‐DIET study: Metabolic response to Dapagliflozin combined with dietary carbohydrate restriction in patients with Type 2 Diabetes Mellitus and Obesity—A longitudinal cohort study
by: Petra Hanson, et al.
Published: (2022-11-01)

Characteristics and Treatments of Patients Enrolled in the CHAMP‐HF Registry Compared With Patients Enrolled in the PARADIGM‐HF Trial
by: Adam D. DeVore, et al.
Published: (2018-06-01)

Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials
by: Magnus O. Wijkman, et al.
Published: (2022-06-01)

Critical Appraisal of the AUGUSTUS Trial
by: Vineet Tatla, et al.
Published: (2020-04-01)

Patient Representativeness With Virtual Enrollment in the PRO‐HF Trial
by: Anshal Gupta, et al.
Published: (2024-01-01)